STOK vs SYRE Stock Comparison

SYRE currently leads STOK in this stock comparison, with AIQ scores of 64 vs 42. The clearest difference is momentum, while STOK has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 22 points
STOK
Healthcare
vs
SYRE
Healthcare
STOK
Stoke Therapeutics, Inc.
Price
$26.68
Day move
+1.83%
AIQ Score
42/100
Best edge
Risk Resilience
Sector
Healthcare
SYRE
Spyre Therapeutics, Inc.
Leads
Price
$104
Day move
+1.06%
AIQ Score
64/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between STOK and SYRE?

SYRE leads the current stock comparison as Spyre Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Stoke Therapeutics, Inc. vs Spyre Therapeutics, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 7/10

SYRE leads

SYRE leads by 22 AIQ points, primarily on Momentum and Value. Wall Street currently favors STOK on target upside.

Competitive: 3 of 6 evidence groups support SYRE, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Stable
STOK

Stoke Therapeutics, Inc.

AIQ Score
42/100
AIQ Edge Score
2/10
SYRE

Spyre Therapeutics, Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors SYRE over STOK, 64 versus 42 as of Nov 15, 2026. SYRE's advantage is driven primarily by stronger momentum and value, while STOK holds the stronger risk resilience profile. SYRE also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors STOK. 3 of 6 covered evidence groups favor SYRE today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. SYRE lead: Stable — the AIQ differential has held near 22 points over 30 sessions.

Compare Stoke Therapeutics, Inc. and Spyre Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

STOK
+558.8%
SYRE
+617.2%

Price return comparison

Growth of $10,000, price only

STOK $65,877 · SYRE $71,724

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare STOK and SYRE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

STOK advantage
0
SYRE advantage
  • Momentum47 vs 81
    SYRE +34
  • Value22 vs 44
    SYRE +22
  • Quality42 vs 61
    SYRE +19
  • Risk Resilience59 vs 53
    STOK +6

3 of 6 evidence groups favor SYRE. SYRE’s edge is concentrated in momentum and value; STOK keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

STOK0 AIQ

Largest factor move: Momentum +1, not enough on its own to move the overall score.

New signals

  • Price Reclaimed 50-Day MA — bullish, trend, medium horizon
  • RSI Midline Reclaim — bullish, momentum, short horizon
SYRE+2 AIQ

Largest factor move: Momentum +2

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.75x)

SYRE's lead widened by 2 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — STOK and SYRE both carry a full feed there.

The central trade-off

SYRE (Spyre Therapeutics, Inc.): the stronger current systematic profile, led by momentum and value.

STOK (Stoke Therapeutics, Inc.): the counter-case, on risk resilience, fundamentals, analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

SYRE

SYRE on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

STOK

STOK on combined revenue and EPS growth.

Value

SYRE

SYRE on the peer-relative Value factor, by 22 points.

Momentum

SYRE

SYRE on the Momentum factor, by 34 points.

Lower downside

STOK

STOK on Risk Resilience, by 6 points.

Analyst upside

STOK

STOK on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors SYRE, analyst targets favor STOK. That disagreement is the most useful thing on this page.

MeasureSTOKSYRENote
Implied upside to target+61.2%+18.1%STOK has more room
Target dispersion0%+11.4%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1418Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor SYRE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreSYRE42 vs 64
FundamentalsSTOKon balanceEPS growth -16.1% vs -161.1%; TTM ROE -20.9% vs -9.1%; gross margin 88.5% vs 50%; operating margin -9.1% vs -276.5% — STOK takes 3 of 4 decided legs, not all of them
ValuationSYREValue 22 vs 44
TechnicalsSYREPrice vs 50-day 0.9% vs 13.7%; vs 200-day -13.3% vs 35.7%
Risk ResilienceSTOKRisk Resilience 59 vs 53
Analyst expectationsSTOKTarget upside 61.2% vs 18.1%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of STOK and SYRE and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 22 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SYRE.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

SYRE lead: Stable — the AIQ differential has held near 22 points over 30 sessions.

May 27STOK leads above the line · SYRE leads belowNov 13
Today
SYRE +22
42 vs 64
7 sessions ago
SYRE +22
40 vs 62
30 sessions ago
SYRE +21
36 vs 57
90 sessions ago
SYRE +25
44 vs 69

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

STOKConflicted

3 bullish / 2 bearish / 2 neutral, conflicted

Only STOK

  • Death Cross Active — bearish, trend, long horizon (16.39%)
  • Price Reclaimed 50-Day MA — bullish, trend, medium horizon
  • RSI Midline Reclaim — bullish, momentum, short horizon
SYREConflicted

4 bullish / 1 bearish / 2 neutral, conflicted

Only SYRE

  • Golden Cross Active — bullish, trend, long horizon (19.32%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 4 more signals that do not separate them: ADX Trend Weakening, ATR Expansion - Breakout Mode, Low Volume Rally Warning, TRIX Bullish Signal.

SYRE leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

STOKNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.83%, AIQ 0 points).

SYREConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.06%, AIQ +2 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1STOK closes the Momentum gap — currently 34 points behind, the largest single contributor to SYRE's edge.
  2. 2STOK's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3SYRE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

STOK leads on balance
MetricSTOKSYRE
Revenue growth (YoY)20.7%0%
EPS growth (YoY)-16.1%-161.1%
Gross margin88.5%50%
Operating margin-9.1%-276.5%
Return on equity (TTM)-20.9%-9.1%
Debt to equity00

Performance

SYRE leads 5 of 6 windows
MetricSTOKSYRE
1 week (5 sessions)0.5%0.1%
1 month (20 sessions)10.4%30.2%
3 months (63 sessions)-17%-0.6%
6 months (126 sessions)-11.3%38.8%
Year to date-15.9%217.5%
1 year (252 sessions)6.2%343.9%

Technicals

SYRE has the stronger structure
MetricSTOKSYRE
RSI (14)51.359.4
ADX (14)17.317.9
Price vs 50-day0.9%13.7%
Price vs 200-day-13.3%35.7%
Volatility (1M, annualized)48.9%59.5%

Risk

STOK is the more resilient
MetricSTOKSYRE
Beta0.961.69
Sharpe ratio0.232.57
Sortino ratio0.354.62
Max drawdown-41.3%-27.8%
Current drawdown-30.4%-4.6%
Annualized volatility53.2%66.7%
Value at risk (95%)-5%-4.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, STOK or SYRE?

On the Algovestiq AIQ Score, SYRE is the stronger of the two as of Nov 15, 2026, scoring 64 against STOK's 42. The edge comes from momentum and value. STOK is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is STOK or SYRE the better buy right now?

SYRE carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor SYRE over STOK?

The composite weights Quality, Value, Momentum and Risk Resilience. SYRE leads Momentum by 34 points; SYRE leads Value by 22 points; SYRE leads Quality by 19 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, STOK or SYRE?

Analyst price targets imply +61.2% upside for STOK and +18.1% for SYRE, so the Street currently favors STOK. That points the opposite way to the AIQ Score, which favors SYRE. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, STOK or SYRE?

SYRE is the better-valued of the two on the peer-relative Value factor. SYRE on the peer-relative Value factor, by 22 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, STOK or SYRE?

STOK on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, STOK or SYRE?

SYRE on the Momentum factor, by 34 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, STOK or SYRE?

STOK is the more resilient of the two, so the other name carries the higher downside risk. STOK on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is STOK more profitable than SYRE?

The profitability evidence is mixed: gross margin 88.5% vs 50%; operating margin -9.1% vs -276.5%; ttm roe -20.9% vs -9.1%. STOK leads on two measures and SYRE on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is SYRE's lead over STOK getting stronger or weaker?

SYRE lead: Stable — the AIQ differential has held near 22 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the STOK vs SYRE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: STOK closes the Momentum gap — currently 34 points behind, the largest single contributor to SYRE's edge; STOK's Death Cross Active resolves — a bearish trend rule currently active against it; SYRE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about STOK and SYRE?

STOK: 3 bullish / 2 bearish / 2 neutral, conflicted. SYRE: 4 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on STOK is Death Cross Active (bearish, long horizon). On SYRE it is Golden Cross Active (bullish, long horizon).

Compare STOK and SYRE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.